Your browser doesn't support javascript.
loading
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
Aebi, S; Sun, Z; Braun, D; Price, K N; Castiglione-Gertsch, M; Rabaglio, M; Gelber, R D; Crivellari, D; Lindtner, J; Snyder, R; Karlsson, P; Simoncini, E; Gusterson, B A; Viale, G; Regan, M M; Coates, A S; Goldhirsch, A.
Afiliación
  • Aebi S; Division of Medical Oncology, Berne University Hospital and Swiss Group for Clinical Cancer research (SAKK), Berne, Switzerland. Electronic address: stefan.aebi@onkologie.ch.
  • Sun Z; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston.
  • Braun D; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston.
  • Price KN; IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, USA.
  • Castiglione-Gertsch M; Medical Onco-Gynecology Unit, Department of Medicine, Geneva University Hospital, Geneva.
  • Rabaglio M; IBCSG Coordinating Center and Inselspital, Berne, Switzerland.
  • Gelber RD; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard School of Public Health, Harvard Medical School, Boston, USA.
  • Crivellari D; Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
  • Lindtner J; Department of Surgical Oncology, Institute of Oncology, Ljulbljana, Slovenia.
  • Snyder R; Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia.
  • Karlsson P; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Simoncini E; Department of Medical Oncology, Spedali Civili di Brescia, Brescia, Italy.
  • Gusterson BA; IBCSG Pathology Review Office, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Viale G; IBCSG Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy.
  • Regan MM; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston.
  • Coates AS; International Breast Cancer Study Group, Berne, Switzerland; School of Public Health, University of Sydney, Australia.
  • Goldhirsch A; Department of Medicine, European Institute of Oncology, Milan, Italy; Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Ann Oncol ; 22(9): 1981-1987, 2011 Sep.
Article en En | MEDLINE | ID: mdl-21282282
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Año: 2011 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Año: 2011 Tipo del documento: Article